Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial" is generating significant coverage in the Health category, with 4 articles from 4 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Medscape, medicalxpress.com, Cardiovascular Business and Oxford Academic. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 7h ago.
Quick answers
Why is "Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELEC" trending?
Because 4 independent news sources published 4 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (4)
- Semaglutide Found to Benefit Frail Patients Medscape · 2d ago
- Weight loss alone does not explain lower heart disease risk for those on semaglutide medicalxpress.com · 2d ago
- Semaglutide is improving the heart health of millions—but how? Experts are stumped Cardiovascular Business · 2d ago
- Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial Oxford Academic · 2d ago
Topics
Related trends
New therapy could stop GLP-1-related muscle loss: Study
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Select Resident Evil Games Are on Sale as Part of Best Buy’s Deal of the Day, Including Requiem
Multiple Resident Evil video games face deep digital and physical price cuts alongside widespread remake and leak reports.
The weight I lost with GLP-1s came back ‘with taxes’
Recent coverage examines rapid weight regain after discontinuing GLP-1 medications like Ozempic, semaglutide, and tirzepatide.
Scientists Found a Surprising Effect of Ozempic. It Involves Your Lungs
New research indicates that GLP-1 medications like Ozempic and Wegovy may significantly reduce the frequency of asthma attacks and COPD flare-ups.
Cravings ‘like heroin withdrawal’: what happens when weight-loss drugs don’t work?
Growing concerns emerge over the 'Ozempidemic' as users report intense cravings and safety risks associated with GLP-1 weight-loss medications.
Novo Nordisk Says Wegovy Shot Helped Children Lose Weight in Trial
Novo Nordisk's Wegovy shows weight-loss results in young children during trial data releases.